B

Blueprint Medicines Corp
D

BPMC

111.190
USD
-0.94
(-0.84%)
Market Closed
Volume
28,084
EPS
-1
Div Yield
-
P/E
-53
Market Cap
7,063,437,927
Related Instruments
    ABBV
    ABBV
    -3.460
    (-2.00%)
    169.130 USD
    AMGN
    AMGN
    -1.26
    (-0.46%)
    273.59 USD
    BMY
    BMY
    0.025
    (0.04%)
    57.075 USD
    GILD
    GILD
    0.070
    (0.08%)
    93.020 USD
    GSK
    GSK
    -0.340
    (-1.01%)
    33.440 USD
    JNJ
    JNJ
    -2.915
    (-1.97%)
    145.250 USD
    LLY
    LLY
    11.37
    (1.53%)
    753.86 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    PFE
    PFE
    -0.621
    (-2.33%)
    26.015 USD
    REGN
    REGN
    -7.47
    (-1.09%)
    679.85 USD
    VRTX
    VRTX
    0.08
    (0.02%)
    428.09 USD
    More
News

Title: Blueprint Medicines Corp

Sector: Healthcare
Industry: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.